Cicas IP LLC v. Stryker Corporation: Surgical Navigation Patent Dispute Ends in Dismissal
Was möchten Sie als Nächstes tun?
Wählen Sie Ihren Weg entsprechend Ihren aktuellen Bedürfnissen:
📋 Fallzusammenfassung
| Fallbezeichnung | Cicas IP LLC v. Stryker Corporation |
| Fallnummer | 2:23-cv-00295 (E.D. Tex.) |
| Gericht | US-Bezirksgericht für den östlichen Bezirk von Texas |
| Dauer | June 2023 – March 2024 9 months |
| Ergebnis | Mit Vorurteil abgewiesen |
| Streitige Patente | |
| Beschuldigte Produkte | Stryker’s endoscopic targeting and surgical navigation systems |
Fallübersicht
Die Parteien
⚖️ Kläger
A non-practicing entity (NPE) asserting patent rights in the medical imaging and surgical navigation technology domain.
🛡️ Beklagter
A Fortune 500 global medical device company. Co-defendant Scopis GmbH specializes in augmented reality surgical navigation.
Das streitige Patent
This case involved U.S. Patent No. 6,850,794 B2, covering an endoscopic targeting method and system. This technology enables precise instrument navigation during minimally invasive surgical procedures using endoscopic imaging guidance.
- • US 6,850,794 B2 — Endoscopic targeting method and system (Application No. US09/957477)
Designing a surgical navigation product?
Check if your medical device design might infringe this or related patents before launch.
Das Urteil und die rechtliche Analyse
Ergebnis
On March 21, 2024, the court accepted the parties’ Joint Stipulation of Dismissal, ordering all claims and causes of action dismissed with prejudice. No damages figure was publicly disclosed, and no injunctive relief was granted. This dismissal “with prejudice” means Cicas IP cannot reassert these specific claims against these defendants in future litigation.
Wichtige rechtliche Fragen
Because the matter resolved before any substantive rulings on claim construction, validity, or infringement, there is no public judicial analysis of how the ‘794 patent claims read on Stryker’s accused endoscopic targeting systems. The joint nature of the dismissal stipulation, combined with the “with prejudice” designation and each-party-bears-own-fees structure, is a signature pattern in confidential patent license settlements in the Eastern District of Texas.
Freedom-to-Operate-Analyse (FTO)
This case highlights critical IP risks in surgical navigation design. Choose your next step:
📋 Die Auswirkungen dieses Falls verstehen
Informieren Sie sich über die spezifischen Risiken und Auswirkungen dieses Rechtsstreits.
- View all related patents in this medical device technology space
- See which companies are most active in surgical navigation patents
- Understand patent claim patterns in endoscopic targeting
🔍 Das Risiko meines Produkts überprüfen
Führen Sie eine umfassende FTO-Analyse für Ihre eigene Medizintechnik oder Ihr Produkt durch.
- Geben Sie Ihre Produktbeschreibung oder technischen Merkmale ein.
- KI identifiziert potenziell blockierende Patente
- Erhalten Sie einen umsetzbaren Risikobewertungsbericht
Hochrisikogebiet
Endoscopic targeting methods
1 Patent geltend gemacht
But from a broader patent family
Verfahrensrechtliche Bedeutung
Illustrates early-stage resolution tactics
✅ Wichtigste Erkenntnisse
Dismissal with prejudice following joint stipulation is a strong indicator of confidential licensing resolution — not necessarily plaintiff or defendant “victory.”
Verwandte Rechtsprechung suchen →The Eastern District of Texas continues to be a high-activity venue for medical device NPE assertions, often leading to rapid pre-trial resolutions.
Präzedenzfälle erkunden →Häufig gestellte Fragen
U.S. Patent No. 6,850,794 B2 (application no. US09/957477), covering an endoscopic targeting method and system, was the sole patent asserted in this case.
The parties filed a Joint Stipulation of Dismissal representing the matter had been resolved, which the court accepted. “With prejudice” means the claims cannot be re-filed against these defendants. No public explanation of the resolution terms was provided.
It reinforces that legacy endoscopic and surgical navigation patents remain viable assertion vehicles against modern medical device companies, and that pre-trial resolutions are common in this space — particularly in the Eastern District of Texas.
Companies in the medical device and surgical navigation space can protect themselves by conducting early and comprehensive Freedom-to-Operate (FTO) analyses, especially for technologies with long development cycles. Thorough IP due diligence during M&A, proactive patent landscaping, and strategic patent filing are also crucial. PatSnap Eureka’s tools help identify potentially blocking patents and navigate complex IP landscapes.
Sind Sie bereit, Ihre Patentstrategie zu stärken?
Schließen Sie sich den über 18.000 Fachleuten aus dem Bereich des geistigen Eigentums an, die PatSnap Eureka nutzen, um mit KI-gestützter Präzision Recherchen zum Stand der Technik durchzuführen, Patentanmeldungen zu erstellen und Wettbewerbslandschaften zu analysieren.
Referenzen
- United States Patent and Trademark Office — U.S. Patent No. 6,850,794 B2
- PACER – Eastern District of Texas Case No. 2:23-cv-00295
- U.S. District Court for the Eastern District of Texas Local Patent Rules
- PatSnap — IP Intelligence Solutions for Medical Device Companies
Dieser Artikel dient ausschließlich zu Informationszwecken und stellt keine Rechtsberatung dar. Alle Angaben zu den Fällen stammen aus öffentlich zugänglichen Gerichtsakten. Informationen zu den Funktionen der Plattform finden Sie auf PatSnap.